Drugs / baliforsen
baliforsen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02312011 | Dec 2014 → Jul 2016 | myotonic dystrophy type 1 | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | baliforsen | “We aimed to investigate the safety of baliforsen (ISIS 598769), an ASO targeting DMPK mRNA.” PMID 36804094 ↗ Mar 2023 |
| Known as | IONIS-598769 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990009 ↗ |
| Known as | IONIS598769 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990009 ↗ |
| Known as | ISIS 598769 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990009 ↗ |
| Route | Subcutaneous | “subcutaneous injections of baliforsen 100 mg” PMID 36804094 ↗ Mar 2023 |